Background: Although positron emission tomography (PET) response to chemotherapy (CT) has prognostic significance in Hodgkin's lymphoma (HL), it is unclear whether patients with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-PET positivity during and/or after CT can be rendered disease free with consolidative involved-field radiotherapy (IFRT).
introduction
The treatment paradigm of Hodgkin's lymphoma (HL) has experienced a dramatic shift over the past 30 years, as combined modality therapy has become the standard of care among patients with early-stage disease [1] . The staging and follow-up of patients have also undergone substantial changes, with functional imaging playing a key role in the management of these patients. Multiple investigators have shown that the presence of residual 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) avidity on positron emission tomography (PET) scan at the completion of CT strongly predicts for subsequent failure [2] [3] [4] [5] . In recent years, emerging data are available on the prognostic significance of early PET response in patients receiving CT for HL [6] [7] [8] [9] . In one study, early PET response has prognostic significance independent of that of the International Prognostic Score for patients with advanced-stage HL [9] . However, limited data are available on the role of consolidative radiotherapy (RT) in the setting of residual FDG avidity either during or at the conclusion of CT, and it is unclear whether the addition of RT may modify the dismal outcome of patients with residual PET-positive disease.
We have previously shown that a substantial percentage of HL patients with residual gallium positivity during or after adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) CT can be rendered disease free with involved-field radiation therapy (IFRT) alone [10] . Our institution started routinely obtaining mid-and/or postchemotherapy PET imaging in 2000 for patients receiving CT for HL. In this paper, we report the failure-free outcomes of patients with and without postchemotherapy PET positivity treated with consolidative RT, and we also discuss the implications of midtreatment PET positivity in the context of routine postchemotherapy radiation treatment.
methods patient eligibility
Patient eligibility was defined by the following characteristics: all patients had a diagnosis of HL who were treated with ABVD-based CT and RT at Dana-Farber Cancer Institute and Brigham and Women's Hospital from 2000 through March 2007. All patients were required to either have a postchemotherapy PET or PET-CT or have achieved a complete response (CR) in a midchemotherapy scan (see below). Patients who were irradiated for recurrent disease or as part of an up-front regimen of high-dose CT with autologous stem-cell rescue were ineligible for this retrospective analysis.
CT treatment
All patients were treated with ABVD-based CT. The number of cycles of treatment given was at the discretion of the treating oncologist. In general, patients with favorable disease (lack of constitutional symptoms, non-bulky disease and less than four sites of involvement) received four cycles of CT while patients with unfavorable factors received six cycles of CT.
PET scanning
All PET or PET-CT imaging studies were carried out at one of the Harvardaffiliated hospitals and interpreted by board-certified nuclear medicine radiologists. Whenever possible, PET response was evaluated based on the 'International Harmonization Project in Lymphoma' [11] . PET positivity was defined as residual FDG uptake above background, and, for residual masses measuring >2 cm, FDG uptake above mediastinal blood pool structures. Residual masses >2 cm with FDG uptake above background but below mediastinal blood pool structures were considered PET negative.
RT treatment
Regardless of PET response during and after CT, all patients included in this study received consolidative IFRT to previously involved nodal regions, as defined by Yahalom and Mauch [12] . The majority of patients underwent CT simulation, and all patients were treated with megavoltage RT. The median dose delivered was 34.8 Gy [interquartile range (IQR) 30.6-36.0]. For patients who were PET positive at the conclusion of CT, the median dose was 36 Gy (IQR 34.8-36). In contrast, patients who were PET negative before RT received a median dose of 30.6 Gy (IQR 30.6-36.2). This difference was of borderline significance (Wilcoxon P = 0.07).
statistical considerations
The primary end point of this study was failure-free survival (FFS), which was defined as the time between the end of radiation treatment and either treatment failure or death from any cause. The date of treatment failure was defined as the date of pathologic confirmation of recurrence or, if no pathological abnormality was obtained, the date of the imaging study that changed patient management from surveillance to treatment. A comparison of radiation dose between patients with postchemotherapy PET-positive and PET-negative disease was carried out with the Wilcoxon rank sum test since the variables were not normally distributed. The comparison of FFS between patients with postchemotherapy PET-positive and PET-negative disease and between patients with interim PET-positive and PET-negative disease was carried out using the log-rank test. The number of treatment failures was too small to support a full multivariable analysis, so a bivariable Cox regression was carried out to assess whether the predictive significance of PET positivity was maintained after controlling for bulky disease, defined as a tumor mass ‡10 cm. All statistical analyses were carried out using SAS software (Raleigh, NC).
results

patient characteristics
A total of 73 patients met criteria for entry into this study. Patient characteristics are described in Table 1 . The vast majority of patients were stage I or II, with only 10% of patients presenting with stage III or IV disease. One-third of patients had bulky disease, all in the mediastinum, and 26% had B symptoms at presentation. Eighty-five per cent of patients had nodular sclerosing histology.
All patients received an ABVD-based regimen. One patient developed doxorubicin-related cardiotoxicity, and ABVD was switched to mechlorethemine, vincristine, procarbazine and prednisone. Another patient was enrolled on a clinical protocol substituting dacarbazine with gemcitabine. All patients but two were delivered a total of either four or six cycles of CT. One patient received two cycles of CT, and one patient received eight cycles of CT. Both of these latter patients were PET negative at the conclusion of CT. A total of 13 patients were PET positive at the conclusion of CT. outcomes by PET response
The median follow-up time for all surviving patients (n = 71) was 3.4 years (IQR 2.3-5.6), with a minimum follow-up of 1.2 years. Of surviving patients who were PET positive after CT (n = 11), the median follow-up time was 3.9 years (IQR 2.9-4.5), with a minimum follow-up of 2.0 years.
significance of postchemotherapy PET positivity. The outcomes following RT are described in Figure 1 . Ninety-seven per cent of patients who were PET negative at the conclusion of CT had no evidence of disease, whereas 69% of patients who were PET positive at the start of RT were free of disease. All three patients who relapsed despite PET negativity at the conclusion of CT were successfully salvaged, whereas only one of the four treatment failures in the PET-positive group was ultimately rendered disease free. When only early-stage patients are considered, 73% (8 of 11) of patients who were PET positive were free of disease. The actuarial 2-year FFS rate was 95% for the PET-negative group, whereas the actuarial 2-year FFS rate was 69% for the PET-positive group. This difference was statistically significant (P < 0.01). Median survival has not been reached in either group. The Kaplan-Meier graph displaying these results is shown in Figure 2A .
significance of interim PET positivity. A total of 46 patients had an interim PET scan, of which 20 showed PET positivity. Thirteen patients became PET negative by the conclusion of CT, and only one (7%) recurred. This patient is now disease free >5 years after salvage therapy. Seven patients showed persistent PET positivity after completion of the ABVD, and two of them recurred. Of these two patients, one is dead from the disease and the second patient is alive with disease. Treatment failed in 3 of the 20 patients with interim PET positivity, yielding a positive predictive value of interim PET of only 15% in the context of consolidative RT.
Of the 26 patients with interim PET-negative findings, one patient became PET positive at the end of CT, but he is currently disease free 35 months since the completion of RT. Of the 25 remaining patients, treatment has failed in only one person (4%), and he was salvaged with high-dose CT and stemcell rescue and has been free of disease for >3 years. The negative predictive value of interim PET was 96%.
The actuarial 2-year FFS rates were 92% and 96% for patients with interim PET-positive/postchemotherapy PET-negative disease and interim PET-negative/postchemotherapy PETnegative disease, respectively, which were significantly superior to that of patients with postchemotherapy PET-positive disease (P = 0.01). The Kaplan-Meier graph displaying these results is shown in Figure 2B .
patterns of failure and salvage treatment Treatment failed in 7 patients at a median of 7 months (IQR 3.9-10) following the completion of RT. A description of patients who relapsed is shown in Table 2 . All seven patients who recurred were treated with high-dose CT and stem-cell rescue. Three patients received additional IFRT as part of the salvage regimen. As described above, all three patients who were PET negative after CT have been successfully salvaged, whereas three of four patients with PET-positive disease after CT had further recurrences after salvage therapy.
predictors of failure
On univariable analysis, only bulky disease (P = 0.02) and postchemotherapy PET positivity (P < 0.01) were statistically significant for recurrent disease. Neither age, stage, nor presence of B symptoms were significant.
The small number of failures precluded a multivariable assessment of predictors of disease recurrence. However, a bivariable Cox regression was carried out, with bulky disease original article Annals of Oncology and PET response as the two covariates. This model showed that residual disease on PET after CT remained a significant predictor of disease recurrence [hazard ratio (HR) 4.8, P = 0.05], even after controlling for disease bulk (HR 3.8, P = 0.13).
discussion
We have shown that a significant percentage of HL patients with residual FDG avidity after ABVD CT can be successfully treated with consolidative IFRT alone. In fact, the 2-year FFS percentage of 69% is identical to the results seen in our previous publication, where RT was given to mid-or postchemotherapy gallium-positive patients [10] . These results indicate that the majority of patients with residual metabolically active lymphoma harbor disease only in the radiographically abnormal lymphadenopathy that can be successfully eradicated by IFRT.
The role of consolidative RT in the setting of residual PET positivity after CT has also been addressed by other investigators. Advani et al. [13] reported on the Stanford V experience, in which 6 of 81 patients had residual PET positivity after CT and before RT. Four of these six patients relapsed after completion of RT. These results are in contrast to the findings of our study, in which only 4 of 13 patients with postchemotherapy PET positivity relapsed after consolidative RT. The discrepancies of our findings may be related to the different chemotherapeutic agents, dose and dose intensity in the Stanford V regimen and ABVD regimen. In addition, all four recurrences in the Stanford study were in-field (one marginal), indicating that doses of 20-36 Gy as was used in the Stanford V regimen may not have been adequate in the presence of residual PET positivity. However, because of the small number of cases in both studies, type I error may also have played a role in the differences of our findings. 
Annals of Oncology original article
The German Hodgkin's Study Group (GHSG) recently reported preliminary results of the HD15 trial for patients with advanced-stage HL [14] . As part of the study, IFRT to 30 Gy was restricted to patients who were PET-positive and had residual disease measuring ‡2.5 cm after bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone-based CT. Among the 59 patients with PET positivity after CT and treated with RT, and with at least 12 months of follow-up, nine relapsed (15%). The favorable outcome despite the residual PET positivity before initiation of RT was compatible with our results, indicating that IFRT to patients with persistently FDG-avid disease renders a majority of them disease free.
Several studies have shown that lack of early interim PET response is a strong predictor of disease recurrence and inferior survival, but these results were largely based on patients with advanced-stage disease and may relate to the less frequent use of radiation treatment. In a prospective study from Copenhagen University Hospital, among the 61 patients with early PET negativity after two cycles of CT, only three progressed or relapsed (5%), as compared with 11 patients with relapsed disease among the 16 patients (69%) with persistent PET positivity [7] . However, the findings appeared to be largely driven by patients with advanced-stage disease in whom consolidative RT was not routinely given. Similarly, in a study by Gallamini et al. [9] , which included patients from the Dutch study [7] among the 210 patients with PET-negative disease after two cycles of CT, only 10 patients (5%) experienced treatment failure, but 43 of 50 (86%) patients with PET positivity after two cycles of CT relapsed [9] . The high positive predictive value of early interim PET results in both of these studies of 69% and 86%, respectively, are in contrast to the relatively low positive predictive value of that found in our study of only 15%. This is likely explained by the use of consolidative RT in all patients in our study. The addition of consolidative RT may dramatically reduce the ability of mid-or post-treatment PET to predict chemoradiotherapy failure. Nevertheless, interim and postchemotherapy PET scan provides useful information in identifying patients who clearly need consolidative RT and perhaps require higher doses of local treatment.
Strengths of the current study include the fact that all patients were treated with ABVD-based CT, a commonly used chemotherapeutic regimen, and all patients were treated with involved fields by one of the two radiation oncologists, such that portal design was as uniform as possible. Each PET or PET-CT study was reviewed by a board-certified nuclear medicine physician at one of the two institutions. Although the minimum follow-up is just over one year for all patients, of individuals who had positive imaging at the conclusion of CT, there was a minimum of 2 years and median of nearly 4 years of follow-up.
Limitations of this study include its retrospective study design leading to potential selection bias; less favorable patients with PET-positive disease may have been directly treated with high-dose CT and autologous transplant and were excluded from the study. Since not every patient underwent a PET scan during or after CT, there may have been some bias as to who received such imaging. Finally, since all patients in this study received IFRT regardless of interim or postchemotherapy PET findings, the important question of the role of RT in the setting of CR by PET after CT is not addressed. Preliminary nonrandomized data from the HD15 GHSG trial indicate that among advanced-stage patients [14] , RT can be eliminated if a negative PET is achieved after completion of CT. In contrast, a randomized trial by Picardi et al. [15] showed that among In this trial, patients on the standard arm receive combined modality therapy, whereas patients on the experimental arm undergo PET scan after two cycles of ABVD. If a PET CR is achieved, patients receive CT alone, and if there is residual PET positivity, combined modality therapy is used. The intent of this trial is to provide support for eliminating RT based on early PET response among patients with early-stage disease. However, definitive conclusions from this trial will not be available for some time, as treatment failures after CT alone can manifest many years after the conclusion of therapy. In summary, our experience indicates that in a sizeable subset of patients with residual FDG avidity during or after CT, IFRT of doses of ‡30 Gy can successfully sterilize local residual disease without the need to resort to salvage CT and/or highdose therapy with stem-cell rescue. Radiographic and clinical predictors of treatment response are crucial as we continue to tailor therapy, but it is also important to determine the best salvage regimen if these predictors indicate residual or resistant disease. Both RT and high-dose CT carry different acute and long-term side-effect profiles, and their optimal use requires balancing the likelihood of residual local-only versus distant disease with the differing toxic effects of eradicating them. The traditional concerns with consolidation RT, second malignancies and cardiac disease, will likely be lessened with lower doses, more conformal fields and possibly even the irradiation of involved nodes alone [16, 17] . Similarly, the morbidity after autologous transplant will presumably be lowered as conditioning regimens evolve and ultimately incorporate tailored biological therapies. 
